Kazia Therapeutics Ltd
KZIA7.512USD
-0.148-1.93%
Market hours （ET）Quotes delayed by 15 min
7.26MMarket Cap
--P/E TTM
More Details of Kazia Therapeutics Ltd Company
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd Info
Ticker SymbolKZIA
Company nameKazia Therapeutics Ltd
IPO dateSep 01, 1994
CEODr. John E. Friend, M.D.
Number of employees- -
Security typeDepository Receipt
Fiscal year-endSep 01
AddressThree International Towers Level 24,
CitySYDNEY
Stock exchangeNASDAQ Capital Market Consolidated
CountryAustralia
Postal code2000
Phone1161298780088
Websitehttps://www.kaziatherapeutics.com/
Ticker SymbolKZIA
IPO dateSep 01, 1994
CEODr. John E. Friend, M.D.
Company Executives of Kazia Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 3
Updated: Fri, Oct 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chernett (Jorey)
8.48%
Dauntless Investment Group, LLC
7.15%
Alumni Capital Management LLC
1.75%
Barclays Capital Inc.
1.48%
UBS Financial Services, Inc.
0.18%
Other
80.96%
Shareholders
Shareholders
Proportion
Chernett (Jorey)
8.48%
Dauntless Investment Group, LLC
7.15%
Alumni Capital Management LLC
1.75%
Barclays Capital Inc.
1.48%
UBS Financial Services, Inc.
0.18%
Other
80.96%
Shareholder Types
Shareholders
Proportion
Individual Investor
8.48%
Investment Advisor
7.38%
Investment Advisor/Hedge Fund
1.77%
Research Firm
1.49%
Hedge Fund
0.01%
Bank and Trust
0.01%
Other
80.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
172.58K
10.66%
+130.44K
2025Q2
38
284.07K
17.55%
+238.97K
2025Q1
39
31.11K
2.29%
-13.78K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
137.20K
8.48%
+137.20K
--
Jun 11, 2025
Dauntless Investment Group, LLC
115.77K
7.15%
+115.77K
--
Jun 30, 2025
Alumni Capital Management LLC
28.41K
1.75%
+28.41K
--
Sep 12, 2025
Barclays Capital Inc.
24.00K
1.48%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
2.83K
0.18%
-2.42K
-46.07%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
591.00
0.04%
+209.00
+54.71%
Jun 30, 2025
Armistice Capital LLC
219.00
0.01%
+219.00
--
Sep 30, 2024
Arax Advisory Partners
200.00
0.01%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
196.00
0.01%
--
--
Aug 31, 2025
UBS Switzerland AG
194.00
0.01%
+194.00
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Date
Type
Ratio
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
